10V Stock Chart & Stats
€14.30
-€0.67(-5.16%)
At close: 4:00 PM EDT
€14.30
-€0.67(-5.16%)
Day’s Range― - ―
52-Week Range€4.36 - €14.34
Previous CloseN/A
Volume0.00
Average Volume (3M)219.00
Market Cap
€90.10M
Enterprise Value€498.91M
Total Cash (Recent Filing)€155.10M
Total Debt (Recent Filing)€567.00K
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Oct 29, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.80
Shares Outstanding13,644,467
10 Day Avg. Volume131
30 Day Avg. Volume219
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-12.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.61Price Target Upside128.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces fixed financial obligations and preserves flexibility as Immunic funds clinical development. The improved TTM equity position also provides a stronger capital structure than in 2025, although continued losses could erode that benefit over time.
MS Pipeline PotentialVidofludimus calcium gives Immunic a focused lead program aimed at multiple sclerosis, including a possible expansion into progressive disease. Advancing the program toward confirmatory Phase 3 trials could broaden the addressable opportunity if clinical and regulatory milestones are achieved.
Stronger Financial OversightAdding a director with extensive biopharmaceutical finance and capital-markets experience may strengthen oversight as Immunic approaches pivotal readouts and potential commercialization decisions. That expertise is particularly relevant while the company manages funding needs and development execution.
Bears Say
No Commercial RevenueImmunic remains pre-commercial, so its operating model currently lacks product revenue to support research and development spending. Until a candidate reaches approval and commercialization, business performance will depend primarily on clinical progress and continued access to external capital.
Persistent LossesLarge recurring losses indicate that Immunic has not yet established operating leverage or a self-sustaining earnings base. Continued negative results can consume equity and increase the amount of capital required before the pipeline produces meaningful commercial returns.
High Cash BurnSubstantial ongoing cash consumption makes financing a central requirement for sustaining clinical operations and advancing the pipeline. This dependence can constrain strategic flexibility and exposes the company to funding pressure until revenue begins or spending is materially reduced.
Immunic News
10V FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was €4.36 and its highest was €14.34 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is €90.10M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Oct 29, 2026 which is in 3 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Aug 11, 2026. The company reported -€0.713 earnings per share for the quarter, beating the consensus estimate of -€1.038 by €0.325.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.83.
How many shares outstanding does Immunic have?
Immunic has 13,644,467 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -€0.713 in its last earnings report, beating expectations of -€1.038. Following the earnings report the stock price went down -1.071%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in DE:10V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.61 (128.04% Upside)
€32.61 (128.04% Upside)
Blogger Sentiment
Bullish
DE:10V Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.98%
12-Months-Change
Fundamentals
Return on Equity
-157.89%
Trailing 12-Months
Asset Growth
159.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunic
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
10V Stock 12 Month Forecast
Average Price Target
€32.61
▲(128.04% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―